‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney Cancer

An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.

There are a number of “unanswered questions” regarding the role of stereotactic radiation in the management of metastatic kidney cancer, according to Raquibul Hannan, MD, PhD.

At the 2022 Society for Urologic Oncology (SUO) Annual Meeting, CancerNetwork® spoke with Hannan about his presentation on clinically managing metastatic kidney cancer with the use of stereotactic radiation.

Hannan, a professor in the Department of Radiation Oncology, Urology and Immunology at the University of Texas Southwestern Medical Center in Dallas, said that delaying systemic therapy for oligometastatic disease in favor of stereotactic radiation and ensuring long-term overall survival among patients pose questions that he and his institution aim to address with future research.

Transcript:

So, [there are] a number of unanswered questions. All of these patients we're treating with oligometastases, also [have] micro-metastatic disease, [also known as] disease that we cannot see. The real question is: are we doing a favor to this patient by delaying this systemic therapy, where we are allowing these micro-metastases to grow? And in the short term, of course, we are seeing very good local control rates, but in the long run, are we affecting overall survival? That's one of the critical questions, and to answer that question, we recently designed and got approval to do a large, randomized phase 3, non-inferiority study with overall survival as one of the co-primary endpoints, where we will do just that. This is the ECOG-EAH-211-SOLE trial that we are expected to open in the summer of 2023.

Related Videos
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Experts on RCC
Experts on RCC
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Related Content